Zebrafish Avatar-test predicts patient's tumor response to chemotherapy in breast cancer: a co-clinical study towards personalized medicine
Mendes, R. V.; Ribeiro, J.; Gouveia, H.; Almeida, C. R. d.; Castillo-Martin, M.; Brito, M. J.; Canas-Marques, R.; Batista, E.; Alves, C.; Sousa, B.; Gouveia, P.; Ferreira, M. G.; Cardoso, M. J.; Cardoso, F.; Fior, R.
Show abstract
Chemotherapy remains the mainstay in most high-risk breast cancer (BC) settings, with several equivalent options of treatment. However, the efficacy of each treatment varies between patients and there is currently no test to determine which option will be the most effective for each individual patient. Here, we developed a fast in-vivo test for BC therapy screening: the zebrafish patient derived xenograft model (zAvatars), where in-vivo results can be obtained in just 10 days. To determine the predictive value of the BC zAvatars we performed a clinical study, where zAvatars were treated with the same therapy as the donor-patient and their response to therapy was compared. Our data shows a 100% correlation between patients clinical response to treatment and its matching zAvatar. Altogether, our results suggest that the zAvatar model constitutes a promising in-vivo assay to optimize cancer treatments in truly personalized manner.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment 95%
- Biological activity of a stable 6-aryl-2-benzoyl-pyridine colchicine-binding site inhibitor, 60c, in metastatic, triple-negative breast cancer 95%
- Simultaneous targeting of AMPK and mTOR is a novel therapeutic strategy against prostate cancer 94%
Similar papers in this journal
- SPARC in cancer-associated fibroblasts is an independent poor prognostic factor in non-metastatic triple-negative breast cancer and exhibits pro-tumor activity 95%
- Prelude to Malignancy: A Gene Expression Signature in Normal Mammary Gland from Breast Cancer Patients Suggests Pre-tumorous Alterations and Is Associated with Adverse Outcomes 93%
- Inhibition of the Rho/MRTF pathway improves the response of BRAF-resistant melanoma to PD1/PDL1 blockade 93%
Similar papers in this journal
- ERK3/MAPK6 promotes triple-negative breast cancer progression through collective migration and EMT plasticity 95%
- A dual readout embryonic zebrafish xenograft model of rhabdomyosarcoma to assess clinically relevant multi-receptor tyrosine kinase inhibitors 94%
- Novel kinome profiling technology reveals drug treatment is patient and 2D/3D model dependent in GBM 93%
Similar papers in this journal
- A 'one-two punch' therapy strategy to target chemoresistance in estrogen receptor positive breast cancer 95%
- Targeting FEN1 to enhance efficacy of PARP inhibition in triple-negative breast cancer 94%
- PMAIP1-Mediated Glucose Metabolism and its Impact on the Tumor Microenvironment in Breast Cancer: Integration of Multi-Omics Analysis and Experimental Validation 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.